James Mond
CIK 1554537 · View on SEC EDGAR ↗
First SEC filing: July 25, 2012 · Latest: July 25, 2012
On this page
- Insider at Companies where this person is a reporting insider.
- Insider transactions Every share this person bought or sold, from Form 4 filings.
- Derivatives Options and other derivative holdings reported by this person.
- Initial holdings The stakes this person held when they first started reporting.
- Compensation Executive pay disclosed in company proxy statements.
Insider at
Insider transactions
Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted
| Date | Ticker | Code | Shares | Price | Value | Owned after | Δ own | A/D | vs now |
|---|---|---|---|---|---|---|---|---|---|
| Sept. 8, 2020 | ADMA | P | 4,000 | $2.20 | $8,800 | 73,174 Direct | +5.78% | Acquired | 352.5% (price as of 2026-08-19) |
| Aug. 10, 2020 | ADMA | P | 2,000 | $2.88 | $5,760 | 69,174 Direct | +2.98% | Acquired | 245.7% (price as of 2026-08-19) |
| Aug. 10, 2020 | ADMA | P | 5,000 | $2.88 | $14,400 | 67,174 Direct | +8.04% | Acquired | 245.7% (price as of 2026-08-19) |
| Feb. 11, 2020 | ADMA | P | 4,285 | $3.50 | $14,998 | 22,174 Direct | +23.95% | Acquired | 184.4% (price as of 2026-08-19) |
| May 17, 2019 | ADMA | P | 4,500 | $4.00 | $18,000 | 17,889 Direct | +33.61% | Acquired | 148.9% (price as of 2026-08-19) |
| Nov. 9, 2017 | ADMA | P | 10,000 | $2.15 | $21,500 | 13,389 Direct | +295.07% | Acquired | 363.0% (price as of 2026-08-19) |
| May 3, 2016 | ADMA | P | 770 | $6.50 | $5,005 | 3,389 Direct | +29.40% | Acquired | 53.2% (price as of 2026-08-19) |
| March 16, 2015 | ADMA | P | 1,250 | $8.02 | $10,025 | 2,565 Direct | +95.06% | Acquired | 24.1% (price as of 2026-08-19) |
| May 14, 2014 | ADMA | P | 1,315 | $7.60 | $9,994 | 1,315 Direct | — | Acquired | 31.0% (price as of 2026-08-19) |
P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding
Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.
Derivative holdings (Form 4 Table II)
Options, RSUs and convertible securities reported on Form 4 Table II.
| Date | Ticker | Security | Underlying | Exercise price | Expiration | Shares | A/D |
|---|---|---|---|---|---|---|---|
| Feb. 25, 2021 | ADMA | Employee Stock Option (right to buy) | Common Stock (139,000) | $2.35 | Feb. 25, 2031 | 139,000 | Acquired |
| Feb. 28, 2020 | ADMA | Employee Stock Option (right to buy) | Common Stock (100,000) | $2.92 | Feb. 28, 2030 | 100,000 | Acquired |
| Jan. 23, 2019 | ADMA | Employee Stock Option (right to buy) | Common Stock (200,000) | $3.22 | Jan. 23, 2029 | 200,000 | Acquired |
| Feb. 9, 2018 | ADMA | Employee Stock Option (right to buy) | Common Stock (150,000) | $3.71 | Feb. 9, 2028 | 150,000 | Acquired |
| June 6, 2017 | ADMA | Employee Stock Option (right to buy) | Common Stock (242,546) | $3.66 | June 6, 2027 | 242,546 | Acquired |
| Feb. 14, 2017 | ADMA | Employee Stock Option (right to buy) | Common Stock (22,500) | $5.00 | Feb. 14, 2027 | 22,500 | Acquired |
| Jan. 28, 2016 | ADMA | Options to purchase | Common Stock (6,750) | — | Jan. 28, 2026 | 6,750 | Acquired |
| Oct. 9, 2015 | ADMA | Options to purchase | Common Stock (27,000) | — | Oct. 9, 2025 | 27,000 | Acquired |
| Jan. 30, 2015 | ADMA | Options to purchase | Common Stock (22,000) | — | Jan. 30, 2025 | 22,000 | Acquired |
| June 19, 2014 | ADMA | Options to purchase | Common Stock (29,591) | — | June 18, 2024 | 29,591 | Acquired |
| Nov. 19, 2012 | ADMA | Options to purchase | Common Stock (106,067) | $9.60 | July 18, 2022 | 106,067 | Acquired |
Exercise/conversion price is blank when not applicable (e.g. RSUs).
Initial ownership (Form 3) 1 holding
Securities held when first becoming an insider, per SEC Form 3.
| Date | Ticker | Security | Shares | Ownership |
|---|---|---|---|---|
| July 25, 2012 | ADMA | No securities are beneficially owned | 0 | Direct |
Compensation (DEF 14A)
Matched by name from proxy statements (DEF 14A) — verify against the filing.
ADMA
Chief Scientific Officer and Chief Medical Officer(7)| Fiscal year | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension change | Other | Total |
|---|---|---|---|---|---|---|---|---|
| 2021 | $216,522 | — | $129,250 | $204,200 | — | — | $544,118 | $1,094,090 |
| 2018 | $401,800 | $117,325 | — | $312,230 | — | — | $214,094 | $1,045,449 |
| 2017 | $360,500 | $127,712 | — | $595,838 | — | — | $86,161 | $1,170,211 |
Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.